– Sovaldi Receives Marketing Authorization for Patients with Genotypes 1, 2, 3 or 4 HCV – – High Cure Rates (SVR 12) and Therapy Shortened to Just 12 Weeks for Many Patients – FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 16, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that Health Canada has issued a Notice of Compliance for Sovaldi™ (sofosbuvir) 400 […]
PALO ALTO, Calif., Dec. 16, 2013 /PRNewswire/ — Varian Medical Systems (NYSE:VAR) today announced that Robert H. Kluge has announced his intention to retire as its Senior Vice President and President, Imaging Components Businesses effective February 7, 2014. Varian CEO Dow R. Wilson has named and the Board of Directors has appointed Sunny Sanyal, CEO of T-System, to succeed Kluge. Varian’s Imaging Components Businesses […]
Combination Creates a Global Leader in Aesthetics Transaction Values Solta at Approximately $250 Million Transaction Expected to Close in the First Quarter of 2014 LAVAL, Quebec and HAYWARD, Calif., Dec. 16, 2013 /PRNewswire/ — Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) today announced that it has entered into a definitive agreement under which […]
MALVERN, Pa., Dec. 16, 2013 /PRNewswire/ — Accretive transaction furthers Endo’s transformation into leading specialty healthcare company Builds on Endo’s leadership in pain management through addition of ZECUITY® (sumatriptan iontophoretic transdermal system), the first and only FDA approved patch to treat migraine Proven Endo branded pharmaceuticals commercial team to execute ZECUITY launch, expected in first half 2014 Endo […]
— European Commission Also Approves Expanded Indication for Regimen, Marketed as Eviplera® in the European Union — FOSTER CITY, Calif.–(BUSINESS WIRE)–Dec. 13, 2013– Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved the single tablet HIV-1 regimen Complera® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate) for use in certain virologically-suppressed (HIV RNA <50 copies/mL) adult patients on a stable […]
Patients with ulcerative colitis (UC) can find information, tips and tools to help manage their disease at www.ShireUCentral.com Chesterbrook, PA, US – December 12, 2013 – Shire plc (LSE: SHP, NASDAQ: SHPGY), the global specialty biopharmaceutical company, is pleased to announce the launch ofwww.ShireUCentral.com, an online disease information and resource center for US patients with ulcerative colitis. UC is […]
Data Monitoring Committee recommends continuation of Phase II/III EPOCH study in mild to moderate disease patients Merck also plans to initiate dosing in Phase III study of prodromal disease patients WHITEHOUSE STATION, N.J. December 10, 2013 — (BUSINESS WIRE) –Merck (NYSE:MRK), known as MSD outside the United States and Canada, today provided an update on the […]
Data Presented at American Society of Hematology (ASH) Meeting Demonstrates Therapeutic Levels of Gene Modification in Sangamo’s In Vivo Protein Replacement Platform RICHMOND, Calif., Dec. 10, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of new pre-clinical data demonstrating therapeutic levels of gene modification in non-human primates (NHPs) from its In Vivo Protein Replacement Platform. Based […]
MALVERN, Pa., Dec. 10, 2013 /PRNewswire/ — Endo Health Solutions (NASDAQ: ENDP) today announced that Arthur J. Higgins has been appointed to its Board of Directors, effective immediately. Endo also announced that Joseph C. Scodari, 60, will retire as a director, effective December 31, 2013. Recognized for his strategic capabilities, Mr. Higgins has over 30 […]
Novel Genome-Editing Approach Offers a Potential Cure for Both Diseases RICHMOND, Calif., Dec. 9, 2013 /PRNewswire/ — Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced the presentation of preclinical data from its ZFP Therapeutic program for the treatment and potential cure of both sickle cell disease (SCD) and beta-thalassemia. The data demonstrate that Sangamo’s approach, using its proprietary and highly specific […]